A new study has found that various psychiatric disorders may be associated with an increased risk of developing dementia. The study, which was led by Leah Richmond-Rakerd, reported its findings in “JAMA Psychiatry.”
For their study, the researchers conducted an analysis of data to determine the link between a range of psychiatric disorders and the development of dementia. The analysis’ results indicate that psychiatric disorders are linked to a heightened risk of developing Alzheimer’s disease and other dementias.
The researchers utilized data obtained from the Integrated Data Infrastructure of New Zealand for their research. This database is comprised of health data for all individuals born in the country. It offers a longitudinal source of disease-related information. The researchers included more than 1.7 million people in the study then grouped psychiatric disorders into the following categories: psychological, behavioral and developmental disturbance, and neurotic, mood, substance-use and psychotic disorders. People who hadn’t sought treatment for their psychiatric symptoms were included in the group of persons without psychiatric disorders.
Prior studies by the researchers had discovered that psychiatric disorders are linked with evidence of premature aging as persons grow older.
During this study, the scientists discovered a fourfold heightened risk for developing dementias such as Alzheimer’s disease in individuals who had a prior history of psychiatric disorders. In their report, the researchers noted that the increased risk for developing other dementias was almost sixfold while that of developing Alzheimer’s disease in particular was 2.8.
The researchers added that the increased risk was observed in both women and men as well as in all age groups, explaining that the increases in risk persisted even after they had controlled for the presence of conditions such as traumatic brain injury, cancer, diabetes, chronic obstructive pulmonary disease, gout and coronary heart disease. The group noted that while the risk was slightly reduced when it controlled for socioeconomic conditions as measured by a certain deprivation factor, it was still high.
In addition to this, the researchers highlighted that individuals with psychiatric disorders who developed dementia eventually did so about five and one-half years earlier than the individuals who didn’t suffer from any mental health condition.
The researchers also carried out further analysis to establish the relative risks of different types of psychiatric disorders on dementia development. They discovered considerable increases in risk linked to every category of psychiatric disorders, noting that the risk ranged from 2.9 times greater for those with neurotic disorders to 6.3 times higher for individuals with psychotic disorders.
This research makes it urgent for better treatments, such as those being developed by entities such as Silo Pharma Inc. (OTCQB: SILO) that targeting mental health disorders so that the likelihood of patients developing dementia later in life is diminished.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork.